Fundraising Fox
/Companies
Sign in

T-Knife

Berlin, DE · 6 known investors

Find your way into T-Knife

Sign up to see every warm intro you have to T-Knife

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the T-Knife team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

T-knife Therapeutics is a biopharmaceutical company developing T cell therapies to treat cancer, with an initial focus on solid tumors. It engineers fully human, tumor-specific T cell receptors along with novel CD8 coreceptors and switch receptors, using technology developed at the Max Delbrück Center for Molecular Medicine and Charité – Universitätsmedizin Berlin.

BiotechHealthtech

Founders & leadership

EKElisa Kieback
Elisa KiebackCTO and co-founderShe has expertise in T cell receptors and T cell-based cancer immunotherapies.
TBThomas Blankenstein
Thomas BlankensteinScientific Founder
TSThomas Soloway
Thomas SolowayChief Executive Officer
CLCamille Landis
Camille LandisChief Business Officer / Chief Financial OfficerCamille Landis is Chief Business Officer and Chief Financial Officer of T-Knife Therapeutics, bringing two decades of experience in biotechnology finance, corporate development, strategy, and commercial operations.
PS
Peggy SotiropoulouChief Scientific OfficerPeggy Sotiropoulou is Chief Scientific Officer of T-Knife Therapeutics, a biopharmaceutical company developing T cell therapies for cancer. She has spent over 20 years working in oncology, immunology, and cell therapy, with experience advancing CAR-T, TCR-T, and next-generation cell therapy programs from concept to clinical development.

Investors · 6

Versant Ventures✓ confirmed by T-KnifeSan Francisco · $250K – $5M

How we know: Versant Ventures's portfolio page · the company's own site · a partner's Signal profile · Not right? Tell us

EQT Life Sciences✓ confirmed by T-KnifeAmsterdam · $11M – $66M

How we know: the company's own site · Not right? Tell us

RA Capitallisted by RA CapitalBoston

How we know: RA Capital's portfolio page · Not right? Tell us

Sixty Degree Capitallisted by Sixty Degree CapitalNorth York

How we know: Sixty Degree Capital's portfolio page · Not right? Tell us

Fidelity InvestmentsreportedBoston

How we know: funding news · Not right? Tell us

Funding

SEC filings, press & company announcements

$110M disclosed across 1 round · 2021

Source: company announcements and press reports — follow each round's link for the claim.

Frequently asked questions

What does T-Knife do?
T-knife Therapeutics is a biopharmaceutical company developing T cell therapies to treat cancer, with an initial focus on solid tumors. It engineers fully human, tumor-specific T cell receptors along with novel CD8 coreceptors and switch receptors, using technology developed at the Max Delbrück Center for Molecular Medicine and Charité – Universitätsmedizin Berlin.
Who founded T-Knife?
T-Knife was founded by Elisa Kieback, Thomas Blankenstein.
Who are T-Knife's investors?
T-Knife's investors include Andera Partners, Versant Ventures, EQT Life Sciences, RA Capital, Sixty Degree Capital, Fidelity Investments.
How much funding has T-Knife raised?
T-Knife has disclosed $110M raised across 1 round.
Where is T-Knife headquartered?
T-Knife is headquartered in Berlin, DE.